Drugs / WGb 0302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07362732 | Feb 2026 → Dec 2027 expected | hematopoietic and lymphoid cell neoplasm | Sichuan University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WGb 0302 | “The experimental drug WGb 0302 injection is a BCMA based messenger RNA (mRNA) therapeutic drug, formed by loading mRNA encoding BCMA receptor related proteins onto lipid...” NCT07362732 ↗ |
| Modality | Messenger RNA (mRNA) | “BCMA based messenger RNA (mRNA) therapeutic drug” NCT07362732 ↗ |
| Route | Intramuscular | “deliver them to the body through intravenous or intramuscular injection” NCT07362732 ↗ |
| Route | Intravenous | “deliver them to the body through intravenous or intramuscular injection” NCT07362732 ↗ |